Pfizer Inc. (PFE)
26.38
0.19 (0.73%)
At close: Mar 21, 2025, 3:59 PM
0.73% (1D)
Bid | 26.1 |
Market Cap | 149.48B |
Revenue (ttm) | 61.74B |
Net Income (ttm) | 7.78B |
EPS (ttm) | 1.41 |
PE Ratio (ttm) | 18.71 |
Forward PE | 9.16 |
Analyst | Hold |
Ask | 26.12 |
Volume | 53,113,049 |
Avg. Volume (20D) | 38,618,061 |
Open | 26.13 |
Previous Close | 26.19 |
Day's Range | 26.01 - 26.38 |
52-Week Range | 24.48 - 31.54 |
Beta | 0.54 |
About PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable an...
Industry Drug Manufacturers - General
Sector Healthcare
IPO Date Jun 1, 1972
Employees 81,000
Stock Exchange NYSE
Ticker Symbol PFE
Website https://www.pfizer.com
Analyst Forecast
According to 14 analyst ratings, the average rating for PFE stock is "Hold." The 12-month stock price forecast is $31, which is an increase of 17.54% from the latest price.
Stock ForecastsNext Earnings Release
Pfizer Inc. is scheduled to release its earnings on Apr 29, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 weeks ago
+1.54%
Shares of vaccine makers are trading higher after ...
Unlock content with
Pro Subscription
1 month ago
+2.2%
Shares of vaccine stocks are trading higher as the sector sees volatility amid Robert F. Kennedy Jr.'s nomination as HHS secretary. Sen. Senator Bill Cassidy said Kennedy committed to cooperation and would not remove vaccine information from the CDC website if confirmed.